Product
cabozantinib
Aliases
Cabometyx, CABOMETYX, XL184
Name
CABOMETYX
INN Name
cabozantinib
FDA Approved
Yes
3 clinical trials
1 organization
15 indications
1 document
Indication
cancerIndication
Lung CancerIndication
Renal Cell CarcinomaIndication
Bladder CancerIndication
Castration-resistant Prostate CancerIndication
Triple-Negative Breast CancerIndication
Ovarian CancerIndication
Endometrial CancerIndication
Hepatocellular CarcinomaIndication
Stomach CancerIndication
Esophageal CancerIndication
Colorectal CancerIndication
Head and Neck CancerIndication
Thyroid CancerIndication
NSCLCClinical trial
A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy and Anti-PD-1 (L)1 ImmunotherapyStatus: Withdrawn, Estimated PCD: 2023-12-17
Clinical trial
A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell CarcinomaStatus: Terminated, Estimated PCD: 2022-01-07
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Document
DailyMed Label: CABOMETYXOrganization
Exelixis, Inc.